Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.
[Century Therapeutics]
7992332
{7992332:CCCCCCCC}
apa
50
1
170620
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
